Targeting Tumor Vasculature With an Oncolytic Virus
Caroline J. Breitbach(University of Ottawa), John C. Bell(Ottawa Hospital), Usaf E. Aladl(Robarts Clinical Trials), Naomi S. De Silva(University of Ottawa), Harold Atkins(University of Ottawa), Jennifer M Paterson(University of Ottawa), Manijeh Daneshmand(University of Ottawa), Laura Evgin(University of British Columbia), Dominic G. Roy(University of Ottawa), Julia L. Rintoul(University of Ottawa), Marianne M. Stanford, Brian D. Lichty(McMaster University Medical Centre), Yang Sun(Shanghai Jiao Tong University), David H. Kirn(Alameda Applied Sciences Corporation (United States)), Theresa Falls(Ottawa Hospital), Kelley A. Parato, Aaron Fenster(Robarts Clinical Trials)
Cited by 202
Related Papers
VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents
|Cancer Cell|2003|850
Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus
|Nature Medicine|2000|816
Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial
|The Lancet Oncology|2008|522
A FLUORINATED GLUCOSE ANALOG, 2-FLUORO-2-DEOXY-D-GLUCOSE (F-18)
|Journal of Computer Assisted Tomography|1980|503
Glucose Metabolic Rate Kinetic Model Parameter Determination in Humans: The Lumped Constants and Rate Constants for [ <sup>18</sup> F]Fluorodeoxyglucose and [ <sup>11</sup> C]Deoxyglucose
|Journal of Cerebral Blood Flow & Metabolism|1985|419